Emblem Corp Stock (TSXV: EMC) (OTCQX: EMMBF) - Investor Dashboard

➔ Emblem Corp.
TSX Venture Exchange: EMC
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 103 (10/16/18)
Established: 2013
CEO: Nick Dean

Woodslee Production Facility 

KRL, a wholly-owned subsidiary of Emblem, purchased a pre-existing agricultural production facility in Paris, Ontario (i.e. the “Existing Facility”). The Existing Facility is located on 4.2 acres of industrial (M2 Special Industrial) zoned lands, which are suitable for significant expansion. The Existing Facility has convenient access to Highway #24A (Grand River St, N) and Highway #403. The Existing Facility consists of a 25,000-square-foot production building and a separate 3,500 sq. ft. administration building. In October 2015 Emblem purchased a contiguous 1.2-acre parcel of land with a 5,000 sq. ft. administration building.

The main 25,000-square-foot production building has been renovated to incorporate 2,400 square feet of mothering and vegetation rooms and 3,200 square feet of flowering rooms together with attendant drying, packaging & fulfillment areas, vault area, and administration. The production building also has an additional three growing rooms comprising 4,800 square feet in the aggregate (the “Phase 2 Grow Rooms”) that are currently being completed and equipped and are expected to be put into production in February/March of 2017. The production building high-quality shipping/receiving capability and ample parking. After completion of the Phase 2 Grow Rooms, the production building will allow Emblem to produce about 2,000 kilograms of medical cannabis annually.

Emblem is in the process of adding a fully funded, 30,000-square-foot processing and formulation laboratory to the Paris facility. This space will also include a 5,000-square-foot formulation and analytical laboratory.

Product Innovation Centre

Emblem is in the process of building a cultivation facility in Woodslee, Ontario. The 30,000-square-foot, fully funded facility will feature a 5,000-square-foot formulation and analytical service laboratory built to GMP standards. Emblem will use the facility for the production of oils and derivative products. The facility is slated for completion in the first quarter of 2019. The Product Innovation Centre is scheduled to be operational in the second quarter of 2019. In Q3 2019, the facility is expected to receive GMP certification  and begin exporting products to Germany.


Visit Emblem Corp.,
at www.emblemcannabis.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Emblem Corp., is a client of NCV Media, LLC. Read our full disclaimer.